1339 related articles for article (PubMed ID: 19208346)
1. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients.
ter Borg PC; Schalm SW; Hansen BE; van Buuren HR;
Am J Gastroenterol; 2006 Sep; 101(9):2044-50. PubMed ID: 16848809
[TBL] [Abstract][Full Text] [Related]
3. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.
Corpechot C; Chazouillères O; Poupon R
J Hepatol; 2011 Dec; 55(6):1361-7. PubMed ID: 21703194
[TBL] [Abstract][Full Text] [Related]
4. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R
Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.
Bonnand AM; Heathcote EJ; Lindor KD; Poupon RE
Hepatology; 1999 Jan; 29(1):39-43. PubMed ID: 9862847
[TBL] [Abstract][Full Text] [Related]
6. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
Corpechot C; Poujol-Robert A; Wendum D; Galotte M; Chrétien Y; Poupon RE; Poupon R
Liver Int; 2004 Jun; 24(3):187-93. PubMed ID: 15189267
[TBL] [Abstract][Full Text] [Related]
7. Natural history of pruritus in primary biliary cirrhosis.
Talwalkar JA; Souto E; Jorgensen RA; Lindor KD
Clin Gastroenterol Hepatol; 2003 Jul; 1(4):297-302. PubMed ID: 15017671
[TBL] [Abstract][Full Text] [Related]
8. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid.
Joshi S; Cauch-Dudek K; Wanless IR; Lindor KD; Jorgensen R; Batts K; Heathcote EJ
Hepatology; 2002 Feb; 35(2):409-13. PubMed ID: 11826416
[TBL] [Abstract][Full Text] [Related]
9. Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment.
Huet PM; Vincent C; Deslaurier J; Coté J; Matsutami S; Boileau R; Huet-van Kerckvoorde J
Gastroenterology; 2008 Nov; 135(5):1552-60. PubMed ID: 18722374
[TBL] [Abstract][Full Text] [Related]
10. Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis.
Momah N; Silveira MG; Jorgensen R; Sinakos E; Lindor KD
Liver Int; 2012 May; 32(5):790-5. PubMed ID: 22136310
[TBL] [Abstract][Full Text] [Related]
11. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
Angulo P; Jorgensen RA; Keach JC; Dickson ER; Smith C; Lindor KD
Hepatology; 2000 Feb; 31(2):318-23. PubMed ID: 10655252
[TBL] [Abstract][Full Text] [Related]
12. [Clinical features and prognosis of primary biliary cirrhosis in Korea].
Kim KA; Jeong SH; Lee JI; Yeon JE; Lee HJ; Kwon SY; Chang UI; Min HJ
Korean J Hepatol; 2010 Jun; 16(2):139-46. PubMed ID: 20606498
[TBL] [Abstract][Full Text] [Related]
13. Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis.
Heathcote EJ; Stone J; Cauch-Dudek K; Poupon R; Chazouilleres O; Lindor KD; Petz J; Dickson ER; Poupon RE
Liver Transpl Surg; 1999 Jul; 5(4):269-74. PubMed ID: 10388499
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
[TBL] [Abstract][Full Text] [Related]
15. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid.
Parés A; Caballería L; Rodés J
Gastroenterology; 2006 Mar; 130(3):715-20. PubMed ID: 16530513
[TBL] [Abstract][Full Text] [Related]
16. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
[TBL] [Abstract][Full Text] [Related]
17. The natural history of PBC: has it changed?
Lee YM; Kaplan MM
Semin Liver Dis; 2005 Aug; 25(3):321-6. PubMed ID: 16143947
[TBL] [Abstract][Full Text] [Related]
18. Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?
Kilmurry MR; Heathcote EJ; Cauch-Dudek K; O'Rourke K; Bailey RJ; Blendis LM; Ghent CN; Minuk GY; Pappas SC; Scully LJ; Steinbrecher UP; Sutherland LR; Williams CN; Worobetz LJ
Hepatology; 1996 May; 23(5):1148-53. PubMed ID: 8621147
[TBL] [Abstract][Full Text] [Related]
19. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group.
Poupon RE; Bonnand AM; Chrétien Y; Poupon R
Hepatology; 1999 Jun; 29(6):1668-71. PubMed ID: 10347106
[TBL] [Abstract][Full Text] [Related]
20. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.
Hazzan R; Tur-Kaspa R
J Clin Gastroenterol; 2010; 44(5):371-3. PubMed ID: 19881358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
